Ken Griffin Ultragenyx Pharmaceutical Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $458,394 - $676,704	11,400 Added 48.72%	34,800 $1.93 Million
Q2 2024 Aug 14, 2024	SELL	$37.42 - $51.61 $276,908 - $381,914	-7,400 Reduced 24.03%	23,400 $961,000
Q1 2024 May 15, 2024	BUY	$43.02 - $53.69 $245,214 - $306,033	5,700 Added 22.71%	30,800 $1.44 Million
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $38,076 - $59,028	-1,200 Reduced 4.56%	25,100 $1.2 Million
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $754,272 - $1.01 Million	21,600 Added 459.57%	26,300 $937,000
Q2 2023 Aug 14, 2023	BUY	$37.35 - $52.15 $41,085 - $57,365	1,100 Added 30.56%	4,700 $216,000
Q1 2023 May 15, 2023	SELL	$36.99 - $48.71 $1.97 Million - $2.6 Million	-53,300 Reduced 93.67%	3,600 $144,000
Q4 2022 Feb 14, 2023	SELL	$33.72 - $46.33 $1.23 Million - $1.69 Million	-36,400 Reduced 39.01%	56,900 $2.64 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $2.94 Million - $4.86 Million	73,500 Added 371.21%	93,300 $3.86 Million

325

85.6M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.1B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.